Skip to main content
SpringerLink
Log in

Tigecycline

In Community-Acquired Pneumonia

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Tigecycline is a first-in-class glycylcycline, broad-spectrum, intravenous antibacterial developed to overcome the two major mechanisms of tetracycline resistance (ribosomal protection and efflux). The drug has been in use since 2005 for complicated intra-abdominal infections, and complicated skin and soft tissue structure infections, but is currently being assessed in the US for community-acquired pneumonia (CAP) in adults.

  • ▴ In vitro, tigecycline had good activity against a range of Gram-positive, Gram-negative and atypical community-acquired respiratory tract pathogens implicated in CAP.

  • ▴ Compared with other antibacterials, tigecycline has a prolonged post-antibiotic effect against key bacteria and a long serum elimination half-life in humans. The drug effectively penetrates lung tissue.

  • ▴ The combined results of two well designed, phase III studies demonstrated that tigecycline 100 mg initially, followed by 50 mg every 12 hours for 7–14 days was not inferior to recommended dosages of levofloxacin in the treatment of hospitalized patients with CAP. Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.

  • ▴ Tigecycline was generally well tolerated in patients with CAP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar; 44 Suppl. 2: S27–72

    Article  PubMed  CAS  Google Scholar 

  2. Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006; 4(1): 9–25

    Article  PubMed  CAS  Google Scholar 

  3. Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65(18): 2623–35

    Article  PubMed  CAS  Google Scholar 

  4. Bergeron J, Ammirati M, Danely D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40(9): 2226–8

    PubMed  CAS  Google Scholar 

  5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial suscepibility testing; eighteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Jan

    Google Scholar 

  6. Tygacil® (tigecycline) for injection. US prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals Inc, 2007

    Google Scholar 

  7. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Grampositive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49(3): 201–9

    Article  PubMed  CAS  Google Scholar 

  8. Fritsche TR, Sader HS, Stilwell MG, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005; 52(3): 187–93

    Article  PubMed  CAS  Google Scholar 

  9. Hesje C, Borsos S, Blondeau J. The impact of blood in media on the determination of mutant prevention concentration testing of tigecycline against clinical isolates of Streptococcus pneumoniae [abstract no. P605 plus poster]. 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19–22; Barcelona

  10. Pillar CM, Draghi DC, Dowzicky MJ, et al. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and E-test. J Clin Microbiol 2008 Sep; 46(9): 2862–7

    Article  PubMed  CAS  Google Scholar 

  11. T.E.S.T. Tigecycline Evaluation and Surveillance Trial [online]. Available from URL: http://www.testsurveillance.com [Accessed 2008 Nov 4]

  12. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008 Apr; 60(4): 421–7

    Article  PubMed  CAS  Google Scholar 

  13. Papaparaskevas J, Tsakris A, Tzouvelekis L, et al. The in vitro activity of tigecycline against 2,423 clinical isolates: comparison of the EUCAST and the FDA approved breakpoints [abstract no. P687]. 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19–22; Barcelona

  14. Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level floroquinolone MIC values. Diagn Microbiol Infect Dis 2007; 58: 9–17

    Article  PubMed  CAS  Google Scholar 

  15. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydi trachomatis. Int J Antimicrob Agents 2000; 16: 61–3

    Article  PubMed  CAS  Google Scholar 

  16. Edelstein PH, Weiss WJ, Edelstein MAC. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47(2): 533–40

    Article  PubMed  CAS  Google Scholar 

  17. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalforpristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalopristin, and telithromycin compared to their susceptibilites to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45(9): 2604–8

    Article  PubMed  CAS  Google Scholar 

  18. Nord CE, Silierström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006 Oct; 50(10): 3375–80

    Article  PubMed  CAS  Google Scholar 

  19. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis 2007 Nov; 59(3): 347–9

    Article  PubMed  CAS  Google Scholar 

  20. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20 (9 Pt 2): 219–3S

    Article  Google Scholar 

  21. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodymic activites of two glycylcyclines (GAR-936 and WAY-152,288) against various Gram-positive and Gram-negative bacteria. Anitmicrob Agents Chemother 2000 Apr; 44: 943–9

    Article  Google Scholar 

  22. Hirata T, Saito A, Nishino K, et al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48(6): 2179–84

    Article  PubMed  CAS  Google Scholar 

  23. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470–80

    Article  PubMed  CAS  Google Scholar 

  24. Ruzin A, Visalli MA, Keeney D, et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49(3): 1017–22

    Article  PubMed  CAS  Google Scholar 

  25. Ednie LM, Kosowska-Shick K, Appelbaum PC. Comparative ability of tigecycline to select for resistant pneumococcal mutants by single-step methodology [abstract no. E297 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)

  26. Bouchillon S, Johnson B, Hackel M, et al. A global perspective of antimicrobial in vitro activity from the T.E.S.T. program: annual analysis from 2004–2007 [abstract no. P676 plus poster]. 18th European Congress of Clinical Microbiology and Infectious Diseases; 2008 Apr 19–22; Barcelona

  27. Salvatore CM, Katz-Gaynor K, McCracken GH, et al. Tigecycline therapy significantly reduces inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia [abstract no. B401]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)

  28. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49(1): 220–9

    Article  PubMed  CAS  Google Scholar 

  29. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of 14C tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007 Sep; 35(9): 1543–53

    Article  PubMed  CAS  Google Scholar 

  30. Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005 Jun 1; 25(6): 523–9

    Article  PubMed  CAS  Google Scholar 

  31. Ong CT, Babalola CP, Nightingale CH, et al. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005 Sep; 56: 498–501

    Article  PubMed  CAS  Google Scholar 

  32. Rubino CM, Bhavnani S, Forrest A, et al. Pharmacokinetic-pharmacodynamic analysis for efficacy of tigecycline in patients with hospital- or community-acquired pneumonia [abstract no. A-588]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)

  33. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43(4): 518–24

    Article  PubMed  CAS  Google Scholar 

  34. Noreddin AM, Salem AH, Haynes VM, et al. Pharmacodynamic profiling of dalbavancin, daptomycin, tigecycline, linezolid and vancomycin in the treatment of community acquired and hospital acquired methicillin resistant Staphylococcus aureus (CA-MRSA and HA-MRSA): Monte Carolo simulation analysis [abstract no. 451]. 45th Annual Meeting of the Infectious Diseases Society of America; 2007 Oct 4–7; San Diego (CA)

  35. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Jul; 61(3): 329–38

    Article  PubMed  CAS  Google Scholar 

  36. Levaquin® (levofloxacin). US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2008 Sep

    Google Scholar 

Download references

Acknowledgements and Disclosure

The manuscript was reviewed by: H.M. Lode, Research Centre for Medical Studies, Charité Universitätsmedizin Berlin, Berlin, Germany; L.A. Mandell, Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Kate McKeage & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Kate McKeage & Gillian M. Keating

Authors
  1. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kate McKeage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, K., Keating, G.M. Tigecycline. Drugs 68, 2633–2644 (2008). https://doi.org/10.2165/0003495-200868180-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0003495-200868180-00008

Keywords

Search

Navigation